title: Phacoemulsification considerations in nonhuman primates.
abstract: OBJECTIVE
  To describe the pre-surgical, surgical, and post-surgical considerations for phacoemulsification in non-human primates.
  
  
  METHODS
  Records of non-human primates that underwent phacoemulsification by the Ophthalmology Services of FHCV-UAB and HCV-UM, between 2003 and 2009 were reviewed.
  
  
  RESULTS
  Five primates were represented: one gorilla, one chimpanzee, one pygmy marmoset, one orangutan, and one chacma baboon. Three were males and two females, of a median age of 16.8 years. Four primates presented bilateral cataracts and one unilateral (n = 9 eyes). Cataracts were immature in two eyes, mature in four and hypermature in 3. One-handed phacoemulsification was used in seven eyes and a two-handed technique in 2. Intraocular lenses (IOLs), with optic powers between +19.0 and +21.5D, were implanted in the four large-sized primates. All the primates were more active and social after the surgery.
  
  
  CONCLUSIONS
  Phacoemulsification in non-human primates is highly successful and associated with an overall good visual outcome. Nevertheless, specific considerations should be applied in these species.
authors.affiliation: Servei d'Oftalmologia Veterinària, Departament de Medicina i Cirurgia Animal, Fundació Hospital Clínic Veterinari, Facultat de Veterinària, Universitat Autònoma de Barcelona, Barcelona, Spain. marta.leiva@uab.cat
authors.forename: Marta
authors.initials: M
authors.lastname: Leiva
authors.forename: Teresa
authors.initials: T
authors.lastname: Peña
authors.forename: Alejandro
authors.initials: A
authors.lastname: Bayón
authors.forename: Mónica
authors.initials: M
authors.lastname: de León
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Morales
mesh_terms: D000818:Animals; D002144:Callithrix / Q000601:surgery*; D005260:Female; D015186:Hominidae / Q000601:surgery*; D008297:Male; D048549:Papio ursinus / Q000601:surgery*; D018918:Phacoemulsification / Q000662:veterinary*; D011184:Postoperative Period; D016896:Treatment Outcome